Immunotherapy Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Immunotherapy stocks.

Immunotherapy Stocks Recent News

Date Stock Title
May 13 ATNM Actinium Announces Multiple Abstracts Highlighting its Antibody Radiation Conjugates Iomab-B and Actimab-A and Novel Linker Technology for Solid Tumors Accepted for Presentation at the 2024 Society of Nuclear Medicine & Molecular Imaging Annual Meeting
May 12 ATNM A Strong Buy - Actinium Pharmaceuticals Promising AML Treatment With Targeted Radiotherapies
May 11 IMCR Analysts Have Made A Financial Statement On Immunocore Holdings plc's (NASDAQ:IMCR) First-Quarter Report
May 10 ARGX argenx SE (NASDAQ:ARGX) Q1 2024 Earnings Call Transcript
May 10 ALPN Alpine Immune Sciences Inc (ALPN) Reports Q1 2024 Financials Amid Pending Acquisition by Vertex ...
May 10 ALPN Alpine Immune ticks higher as HSR waiting period for Vertex Pharma deal expires
May 9 ALPN Alpine Immune Sciences GAAP EPS of -$0.28 beats by $0.12, revenue of $7.03M beats by $3.51M
May 9 ARGX argenx SE (ARGX) Q1 2024 Earnings Call Transcript
May 9 ALPN Alpine Immune Sciences Reports First Quarter 2024 Financial Results
May 9 SNSE Sensei Biotherapeutics GAAP EPS of -$0.32
May 9 SNSE Sensei Biotherapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
May 9 ARGX argenx misses top-line and bottom-line estimates; updates FY24 outlook
May 9 ARGX argenx Reports First Quarter 2024 Financial Results and Provides Business Update
May 8 IMCR Immunocore GAAP EPS of -$0.49 misses by $0.13, revenue of $70.5M beats by $1.32M
May 8 ARGX Argenx SE Q1 2024 Earnings Preview
May 8 IMCR Immunocore Holdings PLC Reports Q1 2024 Earnings: Misses EPS Estimates, Surpasses Revenue Forecasts
May 8 IMNN IMUNON Appoints Director Dr. Stacy R. Lindborg as President and CEO
May 8 IMCR Immunocore reports first quarter financial results and provides a business update
May 7 ARGX argenx announces results of Annual General Meeting of Shareholders
May 7 ALPN Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Q1 2024 Earnings Call Transcript
Immunotherapy

Immunotherapy is the treatment of disease by activating or suppressing the immune system. Immunotherapies designed to elicit or amplify an immune response are classified as activation immunotherapies, while immunotherapies that reduce or suppress are classified as suppression immunotherapies.

In recent years, immunotherapy has become of great interest to researchers, clinicians and pharmaceutical companies, particularly in its promise to treat various forms of cancer.Immunomodulatory regimens often have fewer side effects than existing drugs, including less potential for creating resistance when treating microbial disease.Cell-based immunotherapies are effective for some cancers. Immune effector cells such as lymphocytes, macrophages, dendritic cells, natural killer cells (NK Cell), cytotoxic T lymphocytes (CTL), etc., work together to defend the body against cancer by targeting abnormal antigens expressed on the surface of tumor cells.
Therapies such as granulocyte colony-stimulating factor (G-CSF), interferons, imiquimod and cellular membrane fractions from bacteria are licensed for medical use. Others including IL-2, IL-7, IL-12, various chemokines, synthetic cytosine phosphate-guanosine (CpG) oligodeoxynucleotides and glucans are involved in clinical and preclinical studies.

Browse All Tags